DK2189459T3 - Krystallinsk calciumsalt af 5-methyl-(6S)-tetrahydrofolinsyre - Google Patents

Krystallinsk calciumsalt af 5-methyl-(6S)-tetrahydrofolinsyre

Info

Publication number: DK2189459T3
Authority: DK; Denmark
Prior art keywords: methyl; tetrahydrofolic acid; calcium salt; crystalline calcium; crystalline
Prior art date: 1999-04-15

Application number

DK09178426.4T

Other languages

English (en)

Inventor

Hans Rudolf Mueller

Thomas Egger

Rudolf Moser

Original Assignee

Merck Eprova Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-15

Filing date

2000-04-08

Publication date

2011-04-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4193016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2189459(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-04-08 Application filed by Merck Eprova Ag filed Critical Merck Eprova Ag

2011-04-18 Application granted granted Critical

2011-04-18 Publication of DK2189459T3 publication Critical patent/DK2189459T3/da

Links

159000000007 calcium salts Chemical class 0.000 title abstract 2
ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 2
ZNOVTXRBGFNYRX-OLZOCXBDSA-N (2s)-2-[[4-[[(6r)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid Chemical compound C([C@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-OLZOCXBDSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK09178426.4T 1999-04-15 2000-04-08 Krystallinsk calciumsalt af 5-methyl-(6S)-tetrahydrofolinsyre DK2189459T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH00695/99A CH693905A5 (de)	1999-04-15	1999-04-15	Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
EP00107623A EP1044975B1 (de)	1999-04-15	2000-04-08	Stabiles kristallines Salz der 5-Methyl-(6S)-tetrahydrofolsäure

Publications (1)

Publication Number	Publication Date
DK2189459T3 true DK2189459T3 (da)	2011-04-18

Family

ID=4193016

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK09178426.4T DK2189459T3 (da)	1999-04-15	2000-04-08	Krystallinsk calciumsalt af 5-methyl-(6S)-tetrahydrofolinsyre
DK09178427.2T DK2194057T3 (da)	1999-04-15	2000-04-08	Stabilt krystallinsk calciumsalt af 5-methyl-(6S)-tetrahydrofolinsyre
DK09178428.0T DK2192120T3 (da)	1999-04-15	2000-04-08	Stabilt krystallinsk calciumsalt af 5-methyl-(6S)-tetrahydrofolinsyre
DK00107623.1T DK1044975T3 (da)	1999-04-15	2000-04-08	Stabilt krystallinsk salt af 5-mehtyl-(6S)-tetrahydrofolsyre

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
DK09178427.2T DK2194057T3 (da)	1999-04-15	2000-04-08	Stabilt krystallinsk calciumsalt af 5-methyl-(6S)-tetrahydrofolinsyre
DK09178428.0T DK2192120T3 (da)	1999-04-15	2000-04-08	Stabilt krystallinsk calciumsalt af 5-methyl-(6S)-tetrahydrofolinsyre
DK00107623.1T DK1044975T3 (da)	1999-04-15	2000-04-08	Stabilt krystallinsk salt af 5-mehtyl-(6S)-tetrahydrofolsyre

Country Status (19)

Country	Link
US (1)	US6441168B1 (da)
EP (5)	EP1695975A1 (da)
JP (4)	JP5202774B2 (da)
KR (2)	KR100774012B1 (da)
CN (1)	CN1154648C (da)
AT (2)	ATE496052T1 (da)
AU (1)	AU782641B2 (da)
CA (1)	CA2305926C (da)
CH (1)	CH693905A5 (da)
CY (2)	CY1109874T1 (da)
DE (2)	DE50016064D1 (da)
DK (4)	DK2189459T3 (da)
ES (3)	ES2374371T3 (da)
HU (1)	HU229423B1 (da)
NO (1)	NO325495B1 (da)
PT (4)	PT2192120E (da)
RU (1)	RU2265605C2 (da)
TW (1)	TWI285205B (da)
ZA (1)	ZA200001851B (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH693905A5 (de) *	1999-04-15	2004-04-15	Eprova Ag	Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
JP2004538262A (ja) *	2000-12-14	2004-12-24	タフツユニバーシティー	関節炎状態を治療するための化合物および方法
PT3138566T (pt)	2003-11-17	2022-02-02	Biomarin Pharm Inc	Tratamento de fenilcetonúria com bh4
KR20060051135A (ko) *	2004-09-15	2006-05-19	니프로 가부시키가이샤	안정화된 주사용 수용액 제재
US20100130500A1 (en) *	2004-12-08	2010-05-27	Biomarin Pharmaceutical Inc.	Methods and compositions for the treatment of pulmonary hypertension of the newborn
UY29527A1 (es)	2005-05-13	2006-12-29	Schering Ag	Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
MX2009000256A (es) *	2006-07-06	2009-02-18	Bayer Schering Pharma Ag	Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas.
EP1891959A1 (de) *	2006-08-14	2008-02-27	Bayer Schering Pharma Aktiengesellschaft	Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
US8617597B2 (en)	2006-07-06	2013-12-31	Bayer Intellectual Property Gmbh	Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) *	2006-07-06	2009-07-22	拜耳先灵医药股份有限公司	用于避孕和预防先天性畸形风险的药物制剂
CH698729B1 (de)	2007-05-30	2009-10-15	Cerbios Pharma Sa	Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
EP2027855A1 (de)	2007-08-24	2009-02-25	Bayer Schering Pharma AG	Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität
US20090060997A1 (en) *	2007-08-27	2009-03-05	Christian Seitz	Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and (6s)-5-methyltetrahydrofolate
CA2714340A1 (en) *	2008-02-13	2009-08-20	Bayer Schering Pharma Aktiengesellschaft	Estradiol-containing drug delivery system
AU2009214307A1 (en) *	2008-02-13	2009-08-20	Bayer Intellectual Property Gmbh	Drug delivery system with stabilising effect
JP5856372B2 (ja) *	2008-02-20	2016-02-09	グノーシス・エツセ・ピー・アー	葉酸塩、これらの組成物および使用
HRP20160406T1 (hr)	2009-07-10	2016-05-20	Linzy O. Scott Iii	Postupci i pripravci za liječenje sa štitnjačom povezanih medicinskih stanja sa sniženiim folatima
UY32836A (es)	2009-08-12	2011-03-31	Bayer Schering Pharma Ag	Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
CA2825428C (en)	2010-02-12	2022-06-14	Alexander Vuckovic, M.D., Llc	Compositions and methods for treating depression
EP2646442B1 (en) *	2010-12-03	2015-11-11	Kocak Farma Ilac Ve Kimya San. A.S	A new method for producing antifolate agents having glutamic acid part in their structure
CN102516247A (zh) *	2010-12-15	2012-06-27	连云港金康医药科技有限公司	A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法
EP2502625A1 (en)	2011-03-21	2012-09-26	GMT Fine Chemicals SA	Process for the preparation of crystalline levofolinic acid
CN102775407B (zh) *	2012-01-20	2015-08-05	连云港金康医药科技有限公司	稳定的无定型5-甲基四氢叶酸盐及其制备方法
IN2014DN06942A (da) *	2012-01-20	2015-04-10	Lianyungang Jinkang Hexin Pharmaceutical Co Ltd
CN102702200B (zh) *	2012-04-25	2014-11-12	连云港金康和信药业有限公司	(6rs)-5-甲基四氢叶酸钙盐晶型及其制备方法
CN102584826B (zh) *	2012-01-20	2015-04-29	连云港金康医药科技有限公司	(6s)-5-甲基四氢叶酸盐晶型及其制备方法
US9090623B2 (en)	2012-04-13	2015-07-28	Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd.	Compound JK12A and preparation thereof
CN103450202B (zh) *	2012-06-04	2015-07-01	南京莱因医药科技有限公司	L-5-甲基四氢叶酸与有机碱加成盐的方法
CN103664945B (zh) *	2012-09-07	2016-01-20	南京莱因医药科技有限公司	L-5-甲基四氢叶酸氨基酸盐的制备方法
CN103694239B (zh) *	2012-09-27	2016-12-21	上海科胜药物研发有限公司	一种5‑甲基‑（6s）‑四氢叶酸晶型a及其制备方法
EP2781214A1 (en) *	2013-03-22	2014-09-24	Chemo Research, S.L.	Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
EP3027178A2 (en) *	2013-07-29	2016-06-08	Adare Pharmaceuticals, Inc.	Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture
US20160053281A1 (en)	2013-08-15	2016-02-25	The University Court Of The University Of Edinburgh	Enhanced Expression Of RNA Vectors
US9492421B1 (en)	2013-11-14	2016-11-15	Argent Development Group, Llc	Nutritional supplements for treatment of iron deficiency anemia
US9629846B1 (en)	2013-11-14	2017-04-25	Argent Development Group, Llc	Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
EP2878600B1 (en) *	2013-12-02	2018-06-27	Cerbios-Pharma S.A.	Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol
CN103980279B (zh) *	2014-04-16	2016-07-06	悦康药业集团有限公司	一种甲氨蝶呤化合物及注射用甲氨蝶呤
WO2015193778A1 (en)	2014-06-16	2015-12-23	Mylan Laboratories Ltd.	Crystalline form of levomefolate calcium
WO2016034145A1 (zh) *	2014-09-04	2016-03-10	连云港金康和信药业有限公司	(6s)-5-甲基四氢叶酸或其盐组合物及其制备和应用
CN107812195B (zh) *	2014-09-04	2021-04-20	连云港金康和信药业有限公司	(6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物
CN107812197B (zh)	2014-09-20	2018-09-18	中国药科大学	一种炎症靶向的中性粒细胞递药系统及其应用
WO2016135707A1 (en)	2015-02-27	2016-09-01	Nestec S.A.	Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
WO2016185413A1 (en)	2015-05-20	2016-11-24	Nestec S.A.	Modified release formulations
CN107698591A (zh) *	2015-09-25	2018-02-16	上海华理生物医药有限公司	(6s)-5-甲基四氢叶酸锌盐晶型及其制备方法
DE202015105351U1 (de)	2015-10-09	2016-01-07	Apotheke am Schlossplatz Inh. Mario Ganster e.K.	Diätetische Zusammensetzung
KR101712807B1 (ko)	2015-10-19	2017-03-07	오인숙	스테인레스 빔 제조장치
CN105237539A (zh) *	2015-10-29	2016-01-13	上海应用技术学院	A晶型(6s)-5-甲基四氢叶酸锌盐及其制备方法
CN107304212A (zh) *	2016-04-21	2017-10-31	常州爱诺新睿医药技术有限公司	一种无定型l-5-甲基四氢叶酸氨基酸盐及其制备方法
US11110113B2 (en)	2016-11-03	2021-09-07	Gentelon, Inc.	Compositions and methods for treating depression
CN110461845B (zh) *	2017-03-31	2023-05-12	默克专利股份有限公司	5-甲基-（6s）-四氢叶酸的结晶钠盐
JP7169292B2 (ja)	2017-03-31	2022-11-10	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	５－メチル－（６ｓ）－テトラヒドロ葉酸の結晶性ナトリウム塩
ES2989869T3 (es) *	2017-03-31	2024-11-28	Merck Patent Gmbh	Sal sódica cristalina de ácido 5-metil-(6S)-tetrahidrofólico
EP3461826A1 (en)	2017-09-29	2019-04-03	Aprofol AG	Multifunctional folate salts
JP7502257B2 (ja) *	2018-07-06	2024-06-18	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	５－メチル－（６ｓ）－テトラヒドロ葉酸およびｌ－イソロイシンエチルエステルの結晶性塩
JP7395556B2 (ja) *	2018-07-06	2023-12-11	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	５－メチル－（６ｓ）－テトラヒドロ葉酸及びアミノ酸エチルエステルの結晶塩
ES2966936T3 (es)	2018-07-06	2024-04-25	Merck Patent Gmbh	Sal cristalina que comprende ácido 5-metil-(6S)-tetrahidrofólico y 4-(2-hidroxietil)-morfolina
CN112368050B (zh) *	2018-07-06	2025-12-30	默克专利股份有限公司	5-甲基-(6s)-四氢叶酸和l-缬氨酸乙酯的结晶盐
JP7473526B2 (ja) *	2018-07-06	2024-04-23	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	５－メチル－（６ｓ）－テトラヒドロ葉酸およびｌ－ロイシンエチルエステルの結晶塩
EP3646873A1 (en) *	2018-10-31	2020-05-06	Aprofol AG	Folate salts
EP3666260A1 (en)	2018-12-13	2020-06-17	Laboratorios Leon Farma SA	Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof
WO2021215494A1 (ja)	2020-04-23	2021-10-28	国立大学法人滋賀医科大学	診断支援装置、機械学習装置、診断支援方法、機械学習方法、機械学習プログラムおよびアルツハイマー予測プログラム
KR20230011999A (ko)	2020-05-15	2023-01-25	알파시그마 에스.피.에이.	메틸폴레이트를 포함하는 조성물
EP4501315A1 (en)	2023-08-04	2025-02-05	Lesaffre et Compagnie	Liquid formulations of folates
IT202300027360A1 (it)	2023-12-20	2025-06-20	Lesaffre & Cie	Formulazioni solide di folati

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1572137A (en) *	1977-02-22	1980-07-23	Bioresearch Sas Del Dr Livio C	Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts
US5223500A (en) *	1977-02-22	1993-06-29	Bioresearch S.P.A.	Stable pharmaceutical composition of alkaline or alkaline earth 5-methyl tetrahydrofolate
DE3821875C1 (da)	1988-06-29	1990-02-15	Eprova Ag, Forschungsinstitut, Schaffhausen, Ch
IT1229517B (it) *	1989-01-31	1991-09-03	Bioresearch Spa	Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
CH680731A5 (da)	1990-04-12	1992-10-30	Sapec Fine Chemicals
CH681303A5 (da)	1991-01-16	1993-02-26	Eprova Ag
CH684270A5 (de) *	1991-10-04	1994-08-15	Sapec Fine Chemicals	Verfahren zur Herstellung von Erdalkalimetallsalzen von (6R)-N(10)-Formyl-5,6,7,8-tetrahydrofolsäure.
CH683261A5 (it) *	1991-10-10	1994-02-15	Applied Pharma Res	Procedimento per la preparazione dell'acido metiltetraidrofolico nella forma (6(R,S)(-))N-5 e separazione del diastereoisomero attivo (6(S)(-))N-5) sotto forma di sali.
CH682664A5 (en) *	1991-10-15	1993-10-29	Eprova Ag	Stable salts of 5,10-methylene tetrahydrofolate.
CH682665A5 (de) *	1991-10-29	1993-10-29	Sapec Fine Chemicals	Verfahren zur Reinigung von rohen Erdalkalimetallsalzen von N(5)-Methyl-5,6,7,8-tetrahydrofolsäure.
DE4136921A1 (de) *	1991-11-11	1993-05-13	Knoll Ag	Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure
CH686672A5 (de) *	1992-12-01	1996-05-31	Cerbios Pharma Sa	Verfahren zur Herstellung von (6S)-5,6,7,8-Tetrahydrofolsaeure.
CH686369A5 (de) *	1994-05-09	1996-03-15	Eprova Ag	Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure.
CH689831A5 (de) *	1995-11-07	1999-12-15	Eprova Ag	Stabile kristalline Tetrahydrofolsaeure-Salze.
ATE262799T1 (de)	1996-01-31	2004-04-15	Univ South Alabama	Lebensmittel und vitamin herstellungen mit natürlichem isomeren von reduzierten folaten
CH693905A5 (de) *	1999-04-15	2004-04-15	Eprova Ag	Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.

1999
- 1999-04-15 CH CH00695/99A patent/CH693905A5/de not_active IP Right Cessation
2000
- 2000-04-08 ES ES09178428T patent/ES2374371T3/es not_active Expired - Lifetime
- 2000-04-08 DK DK09178426.4T patent/DK2189459T3/da active
- 2000-04-08 DE DE50016064T patent/DE50016064D1/de not_active Expired - Lifetime
- 2000-04-08 ES ES00107623T patent/ES2336190T3/es not_active Expired - Lifetime
- 2000-04-08 EP EP06010738A patent/EP1695975A1/de not_active Withdrawn
- 2000-04-08 EP EP00107623A patent/EP1044975B1/de not_active Expired - Lifetime
- 2000-04-08 EP EP09178428A patent/EP2192120B1/de not_active Expired - Lifetime
- 2000-04-08 PT PT09178428T patent/PT2192120E/pt unknown
- 2000-04-08 PT PT09178426T patent/PT2189459E/pt unknown
- 2000-04-08 PT PT09178427T patent/PT2194057E/pt unknown
- 2000-04-08 AT AT09178426T patent/ATE496052T1/de active
- 2000-04-08 DK DK09178427.2T patent/DK2194057T3/da active
- 2000-04-08 PT PT00107623T patent/PT1044975E/pt unknown
- 2000-04-08 EP EP09178427A patent/EP2194057B1/de not_active Expired - Lifetime
- 2000-04-08 DK DK09178428.0T patent/DK2192120T3/da active
- 2000-04-08 ES ES09178427T patent/ES2374369T3/es not_active Expired - Lifetime
- 2000-04-08 EP EP09178426A patent/EP2189459B1/de not_active Expired - Lifetime
- 2000-04-08 DE DE50015815T patent/DE50015815D1/de not_active Expired - Lifetime
- 2000-04-08 AT AT00107623T patent/ATE451372T1/de active
- 2000-04-08 DK DK00107623.1T patent/DK1044975T3/da active
- 2000-04-12 TW TW089106827A patent/TWI285205B/zh not_active IP Right Cessation
- 2000-04-12 NO NO20001886A patent/NO325495B1/no not_active IP Right Cessation
- 2000-04-12 AU AU27689/00A patent/AU782641B2/en not_active Expired
- 2000-04-12 ZA ZA200001851A patent/ZA200001851B/xx unknown
- 2000-04-13 JP JP2000112606A patent/JP5202774B2/ja not_active Expired - Lifetime
- 2000-04-13 CA CA002305926A patent/CA2305926C/en not_active Expired - Lifetime
- 2000-04-14 CN CNB00108884XA patent/CN1154648C/zh not_active Expired - Lifetime
- 2000-04-14 KR KR1020000019508A patent/KR100774012B1/ko not_active Expired - Fee Related
- 2000-04-14 RU RU2000109346/04A patent/RU2265605C2/ru active
- 2000-04-14 HU HU0001560A patent/HU229423B1/hu unknown
- 2000-04-17 US US09/551,405 patent/US6441168B1/en not_active Expired - Lifetime
2007
- 2007-05-30 KR KR1020070052657A patent/KR100874368B1/ko not_active Expired - Lifetime
2010
- 2010-03-04 CY CY20101100212T patent/CY1109874T1/el unknown
2011
- 2011-03-03 CY CY20111100250T patent/CY1111313T1/el unknown
2012
- 2012-12-03 JP JP2012264084A patent/JP5675758B2/ja not_active Expired - Lifetime
- 2012-12-03 JP JP2012264086A patent/JP5675760B2/ja not_active Expired - Lifetime
- 2012-12-03 JP JP2012264085A patent/JP5675759B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2000327680A (ja)	2000-11-28
ATE496052T1 (de)	2011-02-15
PT1044975E (pt)	2010-03-09
DE50015815D1 (de)	2010-01-21
DE50016064D1 (de)	2011-03-03
ZA200001851B (en)	2000-12-06
TWI285205B (en)	2007-08-11
KR100874368B1 (ko)	2008-12-16
CA2305926A1 (en)	2000-10-15
HUP0001560A3 (en)	2003-04-28
CY1111313T1 (el)	2015-08-05
CN1154648C (zh)	2004-06-23
JP5675758B2 (ja)	2015-02-25
DK1044975T3 (da)	2010-03-22
EP2189459B1 (de)	2011-01-19
JP5675759B2 (ja)	2015-02-25
EP2192120A1 (de)	2010-06-02
PT2194057E (pt)	2012-01-16
JP2013047278A (ja)	2013-03-07
JP5202774B2 (ja)	2013-06-05
EP2189459A1 (de)	2010-05-26
ATE451372T1 (de)	2009-12-15
HUP0001560A2 (hu)	2001-04-28
HU0001560D0 (en)	2000-06-28
EP2194057A1 (de)	2010-06-09
NO20001886D0 (no)	2000-04-12
NO20001886L (no)	2000-10-16
RU2265605C2 (ru)	2005-12-10
CA2305926C (en)	2008-10-07
AU782641B2 (en)	2005-08-18
AU2768900A (en)	2000-10-19
KR20070062964A (ko)	2007-06-18
DK2194057T3 (da)	2012-01-16
CH693905A5 (de)	2004-04-15
CN1277197A (zh)	2000-12-20
EP1044975A1 (de)	2000-10-18
EP1044975B1 (de)	2009-12-09
KR100774012B1 (ko)	2007-11-08
JP2013047279A (ja)	2013-03-07
JP2013047280A (ja)	2013-03-07
EP1695975A1 (de)	2006-08-30
EP2194057B1 (de)	2011-10-26
PT2189459E (pt)	2011-04-14
DK2192120T3 (da)	2012-01-16
EP2192120B1 (de)	2011-10-26
HU229423B1 (en)	2013-12-30
US6441168B1 (en)	2002-08-27
PT2192120E (pt)	2012-01-16
JP5675760B2 (ja)	2015-02-25
CY1109874T1 (el)	2014-09-10
ES2374369T3 (es)	2012-02-16
KR20010014732A (ko)	2001-02-26
ES2336190T3 (es)	2010-04-09
ES2374371T3 (es)	2012-02-16
NO325495B1 (no)	2008-05-19

Publication	Publication Date	Title
DK2192120T3 (da)	2012-01-16	Stabilt krystallinsk calciumsalt af 5-methyl-(6S)-tetrahydrofolinsyre
DK1163207T3 (da)	2003-12-01	Forbedret fremgangsmåde til fremstillingen af ikke-hygroskopiske salte af L(-)-carnitin
HUP0204034A3 (en)	2004-12-28	Stable salts of novel derivatives of 3,3-diphenylpropylamines
CA2280447A1 (en)	2000-02-17	Pyrrolo¬1,2-a\|pyrazine derivatives as 5ht1a ligands
EP1221439A4 (en)	2003-01-15	TETRAHYDROQUINOLINE DERIVATIVES
WO2003050087A3 (en)	2003-11-20	Novel herbicides
NO990667D0 (no)	1999-02-12	Depeptid-benzamidin som kinogenase-inhibitor
AU2002246728A1 (en)	2002-08-28	Carboline derivatives
MXPA04001685A (es)	2004-05-31	Derivados de sulfonilamino empleados como herbicida.
NO951796D0 (no)	1995-05-08	Stabil krystallinsk (6S)- og (6R)-tetrahydrofolsyre
WO2004035800A3 (en)	2004-08-26	Intermediate cefdinir salts
AU2002213419A1 (en)	2002-04-15	Condensed pyridoindole derivatives
CA2412596A1 (en)	2002-01-03	Cyclic gmp-specific phosphodiesterase inhibitors
WO2001030782A3 (en)	2002-02-28	Novel herbicides
WO2001019826A3 (en)	2001-10-11	Triazolopyrimidine derivatives
ZA200305877B (en)	2004-04-28	Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof.
WO2002038563A3 (en)	2002-09-06	Condensed pyrazindione derivatives as pde inhibitors
CA2423357A1 (en)	2002-02-07	Fused heterocyclic derivatives as phosphodiesterase inhibitors
EA200400877A1 (ru)	2005-02-24	2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи
EP1118615A4 (en)	2002-02-27	PYRIDOPYRAZINE DERIVATIVES SALTS AND CRYSTALS THEREOF
MXPA03009681A (es)	2004-02-12	METODO PARA TRATAMIENTO DE TUMORES POR ADMINISTRACIoN DE TEGAFUR, URACILO, ACIDO FOLINICO, Y CICLOFOSFAMIDA.
TW353070B (en)	1999-02-21	Chloropyridylcarbonyl derivatives
IL160162A0 (en)	2004-07-25	Salts of substituted 1,2,3,4,-tetrahydroisoquinolie-2-carboxylic acid derivatives
ATE530550T1 (de)	2011-11-15	Stabiles kristallines calcium-salz der 5-methyl- (6s)-tetrahydrofolsäure
DK1054002T3 (da)	2006-02-20	Fremgangsmåde til fremstilling af 2-phenyl-3-aminopyridin, substituerede phenylderivater deraf og salte deraf